Days after taking the unusual step, for a Chinese company, of terminating a couple of clinical programs, Bio-Thera Solutions Ltd. said it still plans to continue R&D in antibody-drug conjugates, but with a new technology platform, the company told BioWorld.

A study led by scientists at Osaka University Graduate School of Medicine has identified the previously unknown molecular mechanism underlying bone marrow regeneration after chemotherapy, which damages hematopoietic stem and progenitor cells.

PARIS – Median Technologies SA has unveiled a new clinical development plan for its Ibiopsy platform to provide early diagnosis of lung cancer in at-risk populations using low dose CT scans. Median executives said they hope to demonstrate the potential of deep learning in identifying lung lesions and characterizing them as malignant or benign.